Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals
- 1 September 1992
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 89 (3) , 356-361
- https://doi.org/10.1111/j.1365-2249.1992.tb06962.x
Abstract
SUMMARY: The role of natural killer (NK) cells and their inducible counterparts, lymphokine-activated killer (LAK) cells in AIDS with regard to HIV-1 viral immunosurveillance and the control of secondary opportunistic disease has yet to be established. In this study, we have demonstrated that LAK cells derived from all HIV-1+ groups showed striking increases in their capacity to lyse HIV-1-infected U-937 cells relative to their uninfected U-937 counterparts. Surprisingly, similarly derived LAK cells from healthy seronegative controls showed no differences in their lysis of HIV-1-infected versus uninfected U-937 cells. The differential ability of LAK effectors from seropositive donors to lyse HIV-1-infected targets was demonstrable using a number of U-937 subclones and their HIV-1-infected counterparts. Again, no differences in LAK cell-mediated lysis of HIV-1-infected and uninfected U-937 subclones were observed in seronegative individuals. Our findings that HIV-1+ individuals show selective expansion of non-MHC restricted. HIV-1-directed cytotoxic LAK cells indicate that natural immunity may indeed play a role in HIV-1 viral immunosurveillance.Keywords
This publication has 55 references indexed in Scilit:
- Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disordersAIDS, 1990
- Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1Clinical and Experimental Immunology, 1990
- Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndromeClinical Immunology and Immunopathology, 1989
- Susceptibility to AZT of HIV-l Variants Grown in Epstein-Barr Virus-Transformed B Cell LinesThe Journal of Infectious Diseases, 1989
- Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humansCancer Immunology, Immunotherapy, 1989
- The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitroEuropean Journal of Cancer and Clinical Oncology, 1988
- CELLULAR ANTI-GP120 CYTOLYTIC REACTIVITIES IN HIV-1 SEROPOSITIVE INDIVIDUALSThe Lancet, 1988
- Selective Depletion of Low-Density CD8+, CD16+Lymphocytes During HIV InfectionAIDS Research and Human Retroviruses, 1988
- Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modalityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1986
- Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasmaCancer, 1986